Eagle Pharmaceuticals, Inc. (EGRX)

NASDAQ: EGRX · IEX Real-Time Price · USD
46.76 0.37 (0.80%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap603.85M
Revenue (ttm)179.14M
Net Income (ttm)5.63M
Shares Out12.91M
EPS (ttm)0.43
PE Ratio110.02
Forward PE11.34
Dividendn/a
Ex-Dividend Daten/a
Volume106,165
Open46.02
Previous Close46.39
Day's Range45.61 - 47.52
52-Week Range36.48 - 58.25
Beta0.64
AnalystsBuy
Price Target50.50 (+8.0%)
Earnings Daten/a

About EGRX

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and m...

IndustryBiotechnology
IPO DateFeb 12, 2014
CEOScott Tarriff
Employees106
Stock ExchangeNASDAQ
Ticker SymbolEGRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EGRX stock is "Buy." The 12-month stock price forecast is 50.50, which is an increase of 8.00% from the latest price.

Price Target
$50.50
(8.00% upside)
Analyst Consensus: Buy

News

Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an...

5 days ago - Business Wire

Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update for 2022: Near-Term Business Highlights: Vasopressin: The Co...

2 weeks ago - Business Wire

Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, ...

2 weeks ago - Business Wire

Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company ha...

3 weeks ago - Business Wire

4 High Earnings Yield Stocks Likely to Pay Off Big Time

Summit Hotel (INN), Meritage Homes (MTH), Eagle Pharmaceuticals (EGRX) and BrightSphere (BSIG) could be some attractive bets if you are looking for high earnings yield picks.

Other symbols:BSIGINNMTH
1 month ago - Zacks Investment Research

Eagle Pharmaceuticals (EGRX) Upgraded to Buy: Here's What You Should Know

Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request ...

1 month ago - Business Wire

Eagle Pharmaceuticals Receives FDA Approval for Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company's...

1 month ago - Business Wire

Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

2 months ago - Business Wire

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Eagle Pharmaceuticals Reports Third Quarter 2021 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2021. Bus...

2 months ago - Business Wire

Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tue...

2 months ago - Business Wire

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashi...

4 months ago - Business Wire

Eagle Pharmaceuticals to Present at September Healthcare Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financia...

4 months ago - Business Wire

Eagle Pharmaceuticals Wins Vasopressin Patent Trial

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle's p...

4 months ago - Business Wire

Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent...

4 months ago - Business Wire

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class ...

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA (“...

4 months ago - Business Wire

Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product, Landiolol, in the U.S.  Landiolol, a hospit...

5 months ago - Benzinga

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Eagle Pharmaceuticals Q2 Earnings

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0.93, which beat the estimate o...

5 months ago - Benzinga

Eagle Pharmaceuticals Reports Second Quarter 2021 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2021. Business ...

5 months ago - Business Wire

Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1...

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceutical...

5 months ago - Business Wire

Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Mo...

5 months ago - Business Wire